(CNS) stimulant dextroamphetamine.

Lisdexamfetamine was approved for medical use in the United States in 2007 and in the European Union in 2012. In 2023, it was the 76th most commonly prescribed medication in the United States, with more than 9million prescriptions. It is a Class B controlled substance in the United Kingdom, a Schedule 8 controlled drug in